Why ICH Q7 Compliance Is the New Baseline for Botanical API Procurement

The global shift toward natural-origin therapeutics has collided with increasingly strict regulatory expectations around API quality. Regulatory agencies — the US FDA, EMA, MHRA, and TGA — no longer treat botanical APIs as a separate, softer category distinct from synthetic small molecules. Under ICH Q7, which the EU adopted as GMP Part II in 2005, any material that functions as an active pharmaceutical ingredient must be manufactured under the same documentation, validation, and quality assurance framework as a synthetic active. The era of botanical extracts qualifying as "generally recognized as safe" excipients or exempt from API GMP requirements is effectively over for any supply chain feeding into a regulated-market pharmaceutical product.

The Supply Gap in Botanical API Manufacturing

The vast majority of botanical API volume globally — estimated at over 70% — is produced in China and India under domestic GMP standards that do not satisfy ICH Q7 requirements. This creates a qualification problem for regulated-market pharmaceutical companies: they need a starting material that meets the API GMP standard, but most botanical suppliers cannot provide one. The result is a forced choice between expensive in-house botanical extraction (requiring capital and technical expertise the drug developer typically does not want to deploy) or accepting a supply chain gap that regulators will eventually flag during inspection.

PIC/S-certified botanical API manufacturers are exceptionally rare globally. In Southeast Asia — where raw botanical material supply is geographically concentrated — they are effectively non-existent at commercial scale. Thailand's legalization of kratom cultivation in 2021 and its established tropical agriculture for Amaryllidaceae species and Nelumbo nucifera creates a structural opportunity that only a PIC/S-certified facility in the region is positioned to address with full regulatory traceability.

What ICH Q7 Actually Requires of a Botanical API Facility

During an ICH Q7 audit of a botanical API facility, inspectors systematically evaluate five areas. Understanding these is critical for procurement teams qualifying a botanical API supplier.

1. Raw Material Specification and Identity Testing

ICH Q7 §7.1 requires that starting materials are purchased against approved specifications and that each lot is identity-tested before use. For botanicals, this is technically demanding: a supplier must have validated botanical identification methods — typically HPTLC fingerprinting per Ph.Eur. 2.8.25 — backed by reference standards and an authenticated reference collection of the botanical species. A written raw material specification must define acceptable species, harvest region, moisture content, pesticide residue limits (EU MRL at minimum), heavy metals, and microbiological limits. Generic "Certificate of Analysis from supplier" is not sufficient — the receiving manufacturer must conduct independent identity confirmation on every lot.

2. Process Validation

The extraction, purification, and crystallization train must be process-validated to demonstrate it consistently delivers a product meeting specification. For a botanical API process, this means at minimum three consecutive commercial-scale batches run at the defined parameters (solvent ratios, temperature, flow rates, cycle times) demonstrating that yield, purity, and impurity profile are consistently within specification. Preparative HPLC purification steps — used for chromatography-polished isolates — must include validated column performance qualification, UV detector calibration with reference standards, and documented fraction collection criteria. Process validation is not a one-time exercise: any change to solvent grade, column packing, equipment, or batch size triggers a change control and potentially revalidation per ICH Q7 §13.

3. Analytical Method Validation

Every analytical method used for batch release — assay (purity by HPLC), related substances, residual solvents by GC headspace, heavy metals by ICP-OES, Karl Fischer moisture — must be validated per ICH Q2(R1). For botanical APIs, the specificity of the HPLC assay method is particularly scrutinized: the method must demonstrate chromatographic resolution between the target alkaloid and all known co-extracted alkaloids from the botanical matrix. A Shimadzu LCMS-8060 triple quadrupole system provides the mass-selective detection capability needed to characterize and quantify structurally similar impurity alkaloids at trace levels, a requirement that UV-only HPLC systems cannot reliably meet for complex alkaloid matrices.

4. Change Control, Deviation, and CAPA Systems

ICH Q7 §13 requires a formal change control system that evaluates, approves, and documents any change to starting materials, process equipment, analytical methods, or facility systems before implementation. For botanical APIs, the most common triggers are: change in raw material sourcing region (requires re-qualification of incoming material identity testing); equipment maintenance or replacement; and seasonal variation in raw material alkaloid profile (which may require adjustment of process parameters to maintain purity specification). A digital change control system with electronic batch records — compliant with 21 CFR Part 11 for US FDA submissions — is the standard expected by inspectors from MHRA, TGA, and US FDA alike.

5. Out-of-Specification (OOS) Investigation Procedures

When a batch test result falls outside specification, ICH Q7 §11.15 requires a formal Phase I (laboratory investigation) and Phase II (full investigation including manufacturing review) OOS investigation procedure. The investigation must demonstrate genuine root-cause analysis capability, not simply retesting until a passing result is obtained — a practice that both FDA and EMA inspectors specifically probe for. Invalidating OOS results without documented scientific justification is a common critical observation in API facility inspection reports. A properly designed OOS SOP with training records, completed investigation examples, and clearly delineated responsibilities is one of the first documents inspectors request.

How to Qualify a Botanical API Supplier Under ICH Q7

Pharmaceutical procurement teams qualifying a botanical API supplier should conduct a supplier qualification audit (or request a third-party audit report) that specifically examines the five areas above. Requested documentation should include: the facility's GMP certificate (Thai FDA, PIC/S, or equivalent); a site master file or abbreviated site master file; completed batch manufacturing records for a representative batch; validation protocols and reports for the extraction and purification process; analytical method validation reports; and an impurity profile with mass-spectrometric identification for all observed peaks above 0.05% in the HPLC chromatogram. The absence of any of these documents from a supplier claiming ICH Q7 compliance should be treated as a disqualifying finding.

The Practical Consequence: DMF and ASMF Referencing

An ICH Q7-compliant botanical API manufacturer can file a Drug Master File (Type II DMF with FDA, or Active Substance Master File/ASMF with EDQM) that pharmaceutical customers can reference in their NDA, ANDA, or MAA submissions without disclosing the supplier's proprietary process details to the applicant. This is the mechanism by which a drug developer can demonstrate to the regulatory authority that the API in their drug product is manufactured under GMP, without themselves having conducted the manufacturing. A botanical API supplier that cannot provide a DMF or ASMF — or whose GMP status has not been verified by a recognized regulatory authority — cannot support a drug product regulatory filing in the US, EU, or UK markets. This is the practical floor of what "ICH Q7 compliant" means for procurement purposes.

Phytrax Lifesciences supplies pharmaceutical-grade botanical APIs under ICH Q7 and PIC/S-certified GMP. Contact our business development team for COA, DMF reference letters, and sample logistics.